Galapagos NV
Galapagos NV (GLPG): 8 pipeline candidates · 1 upcoming catalyst · ~11 mo cash runway · 33 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.1 months
D/E 0.05 · 0% dilution
Lead: Phase 3
8 candidates
1 upcoming, next in ~4761d
N/A
A transparent, data-derived signal for Galapagos NVacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.9B
Cash
$40.0M
Quarterly Burn
$257.5M
Runway
11.1 mo
Revenue
$1.1B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| Anti-Tumor Necrosis Factor Alpha Drug | Phase 4 |
| Filgotinib | Phase 4 |
| glpg car t-cell therapy | Phase 3 |
| GLPG CAR T-cell therapy | Phase 3 |
| glpg3667 | Phase 2 |
| GLPG3667 | Phase 2 |
| glpg5101 | Phase 1/Phase 2 |
| GLPG5101 | Phase 1/Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
89
Total value held
$963.2M
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 16,707,477 | $501.2M |
| tang capital management llc | 3,785,991 | $113.6M |
| madison avenue partners, lp | 2,465,179 | $74.0M |
| ecor1 capital, llc | 1,667,119 | $50.0M |
| prosight management, lp | 1,550,000 | $46.5M |
| ameriprise financial inc | 1,424,674 | $42.7M |
| segall bryant & hamill, llc | 854,498 | $26.7M |
| dme capital management, lp | 482,746 | $14.5M |
| susquehanna international group, llp | 462,687 | $13.9M |
| point72 asset management, l.p. | 332,125 | $10.0M |
Showing top 10 of 89 institutional holders of Galapagos NV. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Galapagos NV's pipeline?
Galapagos NV (GLPG) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Galapagos NV's lead drug candidate?
Galapagos NV's most advanced tracked candidate is Anti-Tumor Necrosis Factor Alpha Drug (Phase 4) for Rheumatoid Arthritis.
What is Galapagos NV's next catalyst?
Galapagos NV's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Long-term Follow-up Study for Patients Treated With Galapagos CAR T-cell Therapies" — expected July 1, 2039.
What is Galapagos NV's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Galapagos NV has approximately 11.1 months of cash runway.
What is Galapagos NV's market capitalization?
Galapagos NV's market capitalization is approximately $1.9B.
Get the full picture on Galapagos NV
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.